KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

PURPOSE: We examined the prognostic impact of specific KRAS mutations in stage III colon adenocarcinoma patients receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF-wild type tumors, since BRAF mutation was associated with poor pro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Yoon, Harry H., Tougeron, David, Shi, Qian, Alberts, Steven R., Mahoney, Michelle R., Nelson, Garth D., Nair, Suresh G., Thibodeau, Stephen N., Goldberg, Richard M., Sargent, Daniel J., Sinicrope, Frank A.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4040326/
https://ncbi.nlm.nih.gov/pubmed/24687927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3140
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki